Axillary Hyperhidrosis – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Axillary Hyperhidrosis – Pipeline Review, H2 2019’, provides an overview of the Axillary Hyperhidrosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Axillary Hyperhidrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Axillary Hyperhidrosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Axillary Hyperhidrosis

– The report reviews pipeline therapeutics for Axillary Hyperhidrosis by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Axillary Hyperhidrosis therapeutics and enlists all their major and minor projects

– The report assesses Axillary Hyperhidrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Axillary Hyperhidrosis”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Axillary Hyperhidrosis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Axillary Hyperhidrosis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“Brickell Biotech Inc

DelNova Inc

Dermata Therapeutics LLC

Dermavant Sciences Inc

Dermira Inc

Dr. August Wolff GmbH & Co KG Arzneimittel

Medytox Inc

Revance Therapeutics Inc”

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Axillary Hyperhidrosis Overview

Axillary Hyperhidrosis Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Axillary Hyperhidrosis Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Axillary Hyperhidrosis Companies Involved in Therapeutics Development

Allergan Plc

Brickell Biotech Inc

Dermira Inc

Dr. August Wolff GmbH & Co KG Arzneimittel

GlaxoSmithKline Plc

TheraVida Inc

Axillary Hyperhidrosis Drug Profiles

(oxybutynin + pilocarpine) Drug Profile

Product Description

Mechanism Of Action

R&D Progress

botulinum toxinA Drug Profile

Product Description

Mechanism Of Action

R&D Progress

glycopyrrolate Drug Profile

Product Description

Mechanism Of Action

R&D Progress

glycopyrronium tosylate Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sofpironium bromide Drug Profile

Product Description

Mechanism Of Action

R&D Progress

umeclidinium bromide Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Axillary Hyperhidrosis Dormant Projects

Axillary Hyperhidrosis Discontinued Products

Axillary Hyperhidrosis Product Development Milestones

Featured News & Press Releases

Feb 20, 2018: Sofpironium Bromide Demonstrates Promising Potential as a Safe and Effective First-Line Treatment for Primary Axillary Hyperhidrosis (Excessive Underarm Sweating)

Feb 17, 2018: New Data in Pediatric Patients with Axillary Hyperhidrosis Presented During Late-Breaking Research Forum at the 76th Annual Meeting of the American Academy of Dermatology

Feb 12, 2018: Dermira Showcases Commitment to Hyperhidrosis Education and Treatment at Leading Dermatology Conference

Nov 06, 2017: Dermira Announces that FDA Accepts New Drug Application for Glycopyrronium Tosylate for the Treatment of Patients with Primary Axillary Hyperhidrosis

Oct 24, 2017: Brickell Biotech Announces Positive Phase 2b Study Results for BBI-4000 (Sofpironium Bromide) in Subjects with Primary Axillary Hyperhidrosis

Oct 13, 2017: Dermira Highlights New Long-Term Safety Data for Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis at Fall Clinical Dermatology Conference

Sep 13, 2017: Dermira Presents New Data Showing Impact of Primary Axillary Hyperhidrosis on Patients

Sep 07, 2017: Dermira To Present New Data on Phase 3 Glycopyrronium Tosylate Clinical Program At Leading European Dermatology Congress

Mar 21, 2017: Dermira Presents New Data Highlighting Patient Outcomes in Axillary Hyperhidrosis at Maui Derm Meeting

Mar 17, 2017: Dermira to Present Data on Glycopyrronium Tosylate Clinical Program at Annual Maui Derm Meeting

Mar 03, 2017: Dermira Presents New Data in Primary Axillary Hyperhidrosis at American Academy of Dermatology 2017 Annual Meeting

Feb 27, 2017: TheraVida Announces Publication of Phase 2 Results for THVD-102 in Hyperhidrosis

Feb 27, 2017: Dermira Data from DRM04 Clinical Program to Be Presented at American Academy of Dermatology Annual Meeting

Oct 13, 2016: Dermira to Present Data from DRM04 Clinical Program at Fall Clinical Dermatology Conference

Oct 03, 2016: THVD-102 Demonstrates Promising Potential as an Orally Administered Treatment for Hyperhidrosis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

“List of Tables

Number of Products under Development for Axillary Hyperhidrosis, H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Axillary Hyperhidrosis – Pipeline by Brickell Biotech Inc, H2 2019

Axillary Hyperhidrosis – Pipeline by DelNova Inc, H2 2019

Axillary Hyperhidrosis – Pipeline by Dermata Therapeutics LLC, H2 2019

Axillary Hyperhidrosis – Pipeline by Dermavant Sciences Inc, H2 2019

Axillary Hyperhidrosis – Pipeline by Dermira Inc, H2 2019

Axillary Hyperhidrosis – Pipeline by Dr. August Wolff GmbH & Co KG Arzneimittel, H2 2019

Axillary Hyperhidrosis – Pipeline by Medytox Inc, H2 2019

Axillary Hyperhidrosis – Pipeline by Revance Therapeutics Inc, H2 2019

Axillary Hyperhidrosis – Dormant Projects, H2 2019

Axillary Hyperhidrosis – Discontinued Products, H2 2019”

List of Figures

“List of Figures

Number of Products under Development for Axillary Hyperhidrosis, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products by Targets, H2 2019

Number of Products by Stage and Targets, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports